Progress in the treatment of disseminated intravascular coagulation in patients with acute promyelocytic leukemia
10.3760/cma.j.issn.1673-4408.2019.09.014
- VernacularTitle: 急性早幼粒细胞白血病患儿发生弥散性血管内凝血的治疗进展
- Author:
Xiaoyang LIU
1
;
Liangchun HAO
Author Information
1. Department of Pediatric Hematology, Shengjing Hospital of China Medical University, Shenyang 110004, China
- Publication Type:Review
- Keywords:
Acute promyelocytic leukemia;
Disseminated intravascular coagulation;
Anticoagulant therapy
- From:
International Journal of Pediatrics
2019;46(9):674-677
- CountryChina
- Language:Chinese
-
Abstract:
Acute promyelocytic leukemia(APL)is identified as the M3 subtype of acute myelocytic leukemia(AML). One of its clinical features is severe coagulation dysfunction.Most patients could develop disseminated intravascular coagulation(DIC)resulting vital viscera hemorrhage, which is one of the significant causes of early death in APL patients.Early diagnosis and inductive therapy, dynamic monitoring patients′ coagulation index and correcting the abnormal coagulation could prevent the occurrence or progress of DIC, and then improving the early-term survival rate of APL patients.At present, APL is mainly treated from the treatment of primary disease, anticoagulant antifibrinolytic therapy, and alternative therapy.
